Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Measurement of mRNA therapeutics: method development and validation challenges.

Measurement of mRNA therapeutics: method development and validation challenges. The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for the pharmaceutical industry and contract research organizations. This article describes some of the challenges and strategies for performing regulated bioanalysis of modified mRNA therapeutics by comparing the two main analytical approaches - quantitative reverse transcription PCR and branched DNA. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Bioanalysis Pubmed

Measurement of mRNA therapeutics: method development and validation challenges.

Bioanalysis , Volume 11 (21): 8 – Apr 13, 2020

Measurement of mRNA therapeutics: method development and validation challenges.


Abstract

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for the pharmaceutical industry and contract research organizations. This article describes some of the challenges and strategies for performing regulated bioanalysis of modified mRNA therapeutics by comparing the two main analytical approaches - quantitative reverse transcription PCR and branched DNA.

Loading next page...
 
/lp/pubmed/measurement-of-mrna-therapeutics-method-development-and-validation-Td8pGC1Pj6

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1757-6180
DOI
10.4155/bio-2019-0120
pmid
31657232

Abstract

The progression of chemically modified mRNA therapeutics through development pipelines is accelerating for many disease indications and the need to assess these analytes is becoming more routine for the pharmaceutical industry and contract research organizations. This article describes some of the challenges and strategies for performing regulated bioanalysis of modified mRNA therapeutics by comparing the two main analytical approaches - quantitative reverse transcription PCR and branched DNA.

Journal

BioanalysisPubmed

Published: Apr 13, 2020

There are no references for this article.